Product Benefits

• Superior Platelet Inhibition: Provides more potent and consistent inhibition of platelet aggregation compared to older antiplatelet agents like clopidogrel.

• Rapid Onset of Action: As a direct-acting drug, it does not require liver activation, allowing it to start working significantly faster during cardiac emergencies.

• Reduces Cardiovascular Death: Clinically proven to lower the risk of death from heart-related causes in patients with a recent history of heart attack or unstable angina.

• Prevents Stent Thrombosis: Highly effective at preventing the formation of blood clots within stents (stent thrombosis) in patients who have undergone percutaneous coronary intervention (PCI).

• Consistent Response: Offers a more predictable antiplatelet effect across different patient types because its efficacy is not dependent on specific genetic metabolic profiles.

• Reversible Binding: Unlike aspirin, the binding of Ticagrelor to the P2Y12 receptor is reversible, which can be advantageous if emergency surgery is required.

• Stroke Risk Reduction: Significantly decreases the likelihood of subsequent ischemic strokes in high-risk cardiovascular patients.

• Dual Antiplatelet Therapy (DAPT) Ready: Specifically formulated to be used in conjunction with low-dose aspirin for maximum protection against recurring thrombotic events.